8-K current report · filed Nov 9, 2026

Larimar Therapeutics, Inc. (LRMR) 8-K Current Report: November 9, 2026

Item 2.02Item 8.01Item EX-99.1Item EX-99.2LRMR overview

Short answer

Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Preliminary liquidity of approximately $128.7 million in cash, equivalents and marketable securities as of September 30, 2026.

Larimar Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary liquidity of approximately $128.7 million in cash, equivalents and marketable securities as of September 30, 2026
  • Financial close and review remain ongoing, creating potential for the liquidity figure to change
  • Updated investor presentation provides the disclosure, while full quarterly financial results remain pending

Item 8.01 · Other Events

  • Completed rolling BLA submission to FDA for accelerated approval of nomlabofusp in Friedreich’s ataxia
  • Regulatory milestone potentially advances nomlabofusp toward FDA review and commercialization
  • Updated corporate presentation signals refreshed investor messaging and program data availability

Item EX-99.1 · Exhibit EX-99.1

  • Completed rolling BLA submission for nomlabofusp, seeking accelerated approval for Friedreich’s ataxia
  • FDA willing to consider skin frataxin as a novel surrogate endpoint, but acceptance and approval remain uncertain
  • Open-label data showed sustained skin frataxin increases and directional clinical improvements versus natural-history references
  • Key catalysts: BLA acceptance early 2027, approval targeted mid-2027, U.S. launch targeted Q3 2027 if approved
  • FORWARD-FA Phase 3 enrollment underway, testing daily treatment over 18 months in participants ages 2 to 40

Item EX-99.2 · Exhibit EX-99.2

  • Completed rolling BLA submission in November 2026, seeking accelerated approval using skin FXN as a novel surrogate endpoint
  • FDA acceptance targeted for early 2027, with potential U.S. approval mid-2027 and launch in Q3 2027
  • Open-label data showed sustained skin FXN increases, reaching asymptomatic-carrier range in 100% of evaluable participants at 1 year and 18 months
  • Clinical evidence remains directional, with a 2.6-point mFARS advantage versus FACOMS at 1 year and 4.6 points at 18 months
  • $128.7 million cash and investments as of September 30, 2026, projected runway into late Q2 2027, creating financing risk before potential approval

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Larimar Therapeutics, Inc. 8-K filings

Get the next LRMR 8-K as it lands

Follow LRMR for push alerts, or ask the research agent what this filing means.